{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:07:18Z","timestamp":1785366438005,"version":"3.55.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-07974-w","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T14:02:05Z","timestamp":1774879325000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative efficacy and long-term survival of CD19\/22 versus CD19 CAR-T immunotherapy in Relapsed\/Refractory B-ALL with TP53 alterations"],"prefix":"10.1186","volume":"24","author":[{"given":"Yutong","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingya","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sining","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqing","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1766-7891","authenticated-orcid":false,"given":"Xiaowen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"issue":"1","key":"7974_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-023-01409-5","volume":"16","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Short NJ, Jain N, Haddad FG, Welch MA, Ravandi F, et al. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades. J Hematol Oncol. 2023;16(1):22.","journal-title":"J Hematol Oncol"},{"issue":"14","key":"7974_CR2","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","volume":"30","author":"SP Hunger","year":"2012","unstructured":"Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children\u2019s oncology group. J Clin Oncol: Off J Am Soc Clin Oncol. 2012;30(14):1663\u201369.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"1","key":"7974_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41572-024-00525-x","volume":"10","author":"L Pagliaro","year":"2024","unstructured":"Pagliaro L, Chen S, Herranz D, Mecucci C, Harrison CJ, Mullighan CG, et al. Acute lymphoblastic leukaemia. Nat Rev Disease Primers. 2024;10(1):41.","journal-title":"Nat Rev Disease Primers"},{"issue":"7","key":"7974_CR4","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1182\/blood-2008-06-164863","volume":"113","author":"D Pulte","year":"2009","unstructured":"Pulte D, Gondos A, Brenner H. Improvement in survival in younger patients with acute lymphoblastic leukemia from the, 1980s, to the early 21st century. Blood. 2009;113(7):1408\u201311.","journal-title":"Blood"},{"issue":"9","key":"7974_CR5","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1182\/blood-2011-09-377713","volume":"120","author":"N G\u00f6kbuget","year":"2012","unstructured":"G\u00f6kbuget N, Kneba M, Raff T, Trautmann H, Bartram C, Arnold R, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood. 2012;120(9):1868\u201376.","journal-title":"Blood"},{"issue":"10","key":"7974_CR6","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1182\/bloodadvances.2020001466","volume":"4","author":"X Zhang","year":"2020","unstructured":"Zhang X, Lu X, Yang J, Zhang G, Li J, Song L, et al. Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features. Blood Adv. 2020;4(10):2325\u201338.","journal-title":"Blood Adv"},{"issue":"1","key":"7974_CR7","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3324\/haematol.2018.199364","volume":"105","author":"S Demir","year":"2020","unstructured":"Demir S, Boldrin E, Sun Q, Hampp S, Tausch E, Eckert C, et al. Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia. Haematologica. 2020;105(1):170\u201381.","journal-title":"Haematologica"},{"issue":"3","key":"7974_CR8","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1158\/2643-3230.BCD-23-0106","volume":"5","author":"C Saygin","year":"2024","unstructured":"Saygin C, Zhang P, Stauber J, Aldoss I, Sperling AS, Weeks LD, et al. Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis. Blood Cancer Discov. 2024;5(3):164\u201379.","journal-title":"Blood Cancer Discov"},{"issue":"3","key":"7974_CR9","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/leu.2016.263","volume":"31","author":"A Stengel","year":"2017","unstructured":"Stengel A, Kern W, Haferlach T, Meggendorfer M, Fasan A, Haferlach C. The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases. Leukemia. 2017;31(3):705\u201311.","journal-title":"Leukemia"},{"issue":"S4","key":"7974_CR10","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/ajh.27655","volume":"100","author":"MV Shah","year":"2025","unstructured":"Shah MV, Arber DA, Hiwase DK. TP53 -mutated myeloid neoplasms: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2025;100(S4):88\u2013115.","journal-title":"Am J Hematol"},{"issue":"8","key":"7974_CR11","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41568-020-0262-1","volume":"20","author":"AJ Levine","year":"2020","unstructured":"Levine AJ. p53: 800 million years of evolution and 40 years of discovery. Nat Rev Cancer. 2020;20(8):471\u201380.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"7974_CR12","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1080\/00365513.2023.2195682","volume":"83","author":"S Firtina","year":"2023","unstructured":"Firtina S, Erbilgin Y, Hatirnaz Ng O, Karaman S, Karakas Z, Celkan TT, et al. Impact of TP53 gene variants on prognosis and survival of childhood acute lymphoblastic leukemia. Scand J Clin Lab Invest. 2023;83(3):187\u201393.","journal-title":"Scand J Clin Lab Invest"},{"key":"7974_CR13","doi-asserted-by":"crossref","unstructured":"Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Csh Perspect Biol. 2010;2(1):a001008.","DOI":"10.1101\/cshperspect.a001008"},{"issue":"3","key":"7974_CR14","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s44321-024-00024-2","volume":"16","author":"J Mueller","year":"2024","unstructured":"Mueller J, Schimmer RR, Koch C, Schneiter F, Fullin J, Lysenko V, et al. Targeting the mevalonate or wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells. EMBO Mol Med. 2024;16(3):445\u201374.","journal-title":"EMBO Mol Med"},{"issue":"11","key":"7974_CR15","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1182\/bloodadvances.2021005859","volume":"6","author":"RR Schimmer","year":"2022","unstructured":"Schimmer RR, Kovtonyuk LV, Klemm N, Fullin J, Stolz SM, Mueller J, et al. TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms. Blood Adv. 2022;6(11):3201\u201306.","journal-title":"Blood Adv"},{"issue":"2","key":"7974_CR16","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/bjc.2017.152","volume":"117","author":"M Forero-Castro","year":"2017","unstructured":"Forero-Castro M, Robledo C, Benito R, Bodega-Mayor I, Rapado I, Hern\u00e1ndez-S\u00e1nchez M, et al. Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia. Brit J Cancer. 2017;117(2):256\u201365.","journal-title":"Brit J Cancer"},{"issue":"1","key":"7974_CR17","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41408-025-01350-5","volume":"15","author":"EJ Harris","year":"2025","unstructured":"Harris EJ, Karaoglu DA, Sukhanova M, Abaza Y, Karantanos T, Eisfeld A, et al. Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults. Blood Cancer J. 2025;15(1):138.","journal-title":"Blood Cancer J"},{"key":"7974_CR18","doi-asserted-by":"publisher","first-page":"1048296","DOI":"10.3389\/fonc.2022.1048296","volume":"12","author":"Z Li","year":"2023","unstructured":"Li Z, Yang K, Song Y, Zhao Y, Wu F, Wen X, et al. CAR-T therapy followed by allogeneic hematopoietic stem cell transplantation for refractory\/relapsed acute B lymphocytic leukemia: long-term follow-up results. Front Oncol. 2023;12:1048296.","journal-title":"Front Oncol"},{"issue":"3","key":"7974_CR19","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00262-021-03009-z","volume":"71","author":"X Zhang","year":"2022","unstructured":"Zhang X, Yang J, Li J, Li W, Song D, Lu X, et al. Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia. Cancer Immunol Immun. 2022;71(3):689\u2013703.","journal-title":"Cancer Immunol Immun"},{"issue":"9","key":"7974_CR20","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1182\/bloodadvances.2024014986","volume":"9","author":"I Aldoss","year":"2025","unstructured":"Aldoss I, Li S, Zhang J, Clark MC, Agrawal V, Pourhassan H, et al. TP53 mutations are associated with CD19\u2212 relapse and inferior outcomes after blinatumomab in adults with ALL. Blood Adv. 2025;9(9):2159\u201372.","journal-title":"Blood Adv"},{"issue":"5","key":"7974_CR21","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. NEJM Evid. 2018;378(5):439\u201348.","journal-title":"NEJM Evid"},{"issue":"16","key":"7974_CR22","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. NEJM Evid. 2014;371(16):1507\u201317.","journal-title":"NEJM Evid"},{"issue":"12","key":"7974_CR23","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1038\/s41375-020-0831-z","volume":"34","author":"J Pan","year":"2020","unstructured":"Pan J, Tan Y, Deng B, Tong C, Hua L, Ling Z, et al. Frequent occurrence of CD19-negative relapse after CD19 CAR T and consolidation therapy in 14 TP53-mutated r\/r B-ALL children. Leukemia. 2020;34(12):3382\u201387.","journal-title":"Leukemia"},{"key":"7974_CR24","doi-asserted-by":"publisher","first-page":"105872","DOI":"10.1016\/j.ebiom.2025.105872","volume":"118","author":"B Gonz\u00e1lez-Mart\u00ednez","year":"2025","unstructured":"Gonz\u00e1lez-Mart\u00ednez B, Gal\u00e1n-G\u00f3mez V, Navarro-Zapata A, Mirones-Aguilar I, Cobo M, Pernas-S\u00e1nchez A, et al. Tandem CD19\/CD22 CAR T-cells as potential therapy for children and young adults with high-risk r\/r B-ALL. Ebiomedicine. 2025;118:105872.","journal-title":"Ebiomedicine"},{"issue":"9","key":"7974_CR25","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1200\/JCO.22.01214","volume":"41","author":"T Wang","year":"2023","unstructured":"Wang T, Tang Y, Cai J, Wan X, Hu S, Lu X, et al. Coadministration of CD19- and CD22-directed Chimeric antigen receptor T-Cell therapy in childhood B-Cell acute lymphoblastic leukemia: a single-arm, multicenter, Phase II Trial. J Clin Oncol: Off J Am Soc Clin Oncol. 2023;41(9):1670\u201383.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"7974_CR26","doi-asserted-by":"publisher","first-page":"1178403","DOI":"10.3389\/fimmu.2023.1178403","volume":"14","author":"NJ Fergusson","year":"2023","unstructured":"Fergusson NJ, Adeel K, Kekre N, Atkins H, Hay KA. A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells. Front. Immunol. 2023;14:1178403.","journal-title":"Front. Immunol"},{"key":"7974_CR27","doi-asserted-by":"publisher","first-page":"954345","DOI":"10.3389\/fonc.2022.954345","volume":"12","author":"L Li","year":"2022","unstructured":"Li L, Wang L, Liu Q, Wu Z, Zhang Y, Xia R. Efficacy and safety of CD22-specific and CD19\/CD22-bispecific CAR-T cell therapy in patients with hematologic malignancies: a systematic review and meta-analysis. Front Oncol. 2022;12:954345.","journal-title":"Front Oncol"},{"issue":"7750","key":"7974_CR28","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","volume":"568","author":"M Hamieh","year":"2019","unstructured":"Hamieh M, Dobrin A, Cabriolu A, van der Stegen SJC, Giavridis T, Mansilla-Soto J, et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature. 2019;568(7750):112\u201316.","journal-title":"Nature"},{"issue":"1","key":"7974_CR29","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41408-023-00819-5","volume":"13","author":"S Liu","year":"2023","unstructured":"Liu S, Zhang X, Dai H, Cui W, Yin J, Li Z, et al. Which one is better for refractory\/relapsed acute B-cell lymphoblastic leukemia: single-target (CD19) or dual-target (tandem or sequential CD19\/CD22) CAR T-cell therapy? Blood Cancer J (New Y). 2023;13(1):60.","journal-title":"Blood Cancer J (New Y)"},{"key":"7974_CR30","doi-asserted-by":"crossref","unstructured":"Cui W, Zhang XY, Li Z, Dai HP, Yin J, Cui QY, et al. Long-term follow-up of tandemCD19\/CD22 CAR T-Cellsin r\/rB-ALL patients with high-risk features. Am J Hematol. 2023;98(11).","DOI":"10.1002\/ajh.27076"},{"key":"7974_CR31","doi-asserted-by":"crossref","unstructured":"Sallman DA, Komrokji RS, Dezern AE, Sebert M, Garcia-Manero G, Rahm\u00e9 R, et al. Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS\/AML. Hemasphere. 2025;9(7):e70164.","DOI":"10.1002\/hem3.70164"},{"key":"7974_CR32","doi-asserted-by":"publisher","first-page":"217264","DOI":"10.1016\/j.canlet.2024.217264","volume":"605","author":"Y Wang","year":"2024","unstructured":"Wang Y, Chang Y, Chen J, Han M, Hu J, Hu J, et al. Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update. Cancer Lett. 2024;605:217264.","journal-title":"Cancer Lett"},{"issue":"2","key":"7974_CR33","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188\u201395.","journal-title":"Blood"},{"issue":"4","key":"7974_CR34","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT Consensus grading for cytokine release syndrome and neurologic Toxicity associated with immune effector cells. Biol Blood Marrow Transplant: J The Am Soc For. 2019;25(4):625\u201338.","journal-title":"Biol Blood Marrow Transplant: J The Am Soc For"},{"issue":"2","key":"7974_CR35","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/pbc.21039","volume":"48","author":"J Henter","year":"2007","unstructured":"Henter J, Horne A, Aric\u00f3 M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124\u201331.","journal-title":"Pediatr Blood Cancer"},{"issue":"23","key":"7974_CR36","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1200\/JCO.2011.34.8144","volume":"29","author":"J Hof","year":"2011","unstructured":"Hof J, Krentz S, van Schewick C, K\u00f6rner G, Shalapour S, Rhein P, et al. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. J Clin Oncol: Off J Am Soc Clin Oncol. 2011;29(23):3185\u201393.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"7974_CR37","doi-asserted-by":"crossref","unstructured":"Salmoiraghi S, Montalvo MLG, Ubiali G, Tosi M, Peruta B, Zanghi P, et al. Mutations of TP53 gene in adult acute lymphoblastic leukemia at diagnosis do not affect the achievement of hematologic response but correlate with early relapse and very poor survival. Haematologica. 2016;101(6):e245\u201348.","DOI":"10.3324\/haematol.2015.137059"},{"issue":"4","key":"7974_CR38","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1200\/JCO.21.02143","volume":"40","author":"R Shouval","year":"2022","unstructured":"Shouval R, Alarcon Tomas A, Fein JA, Flynn JR, Markovits E, Mayer S, et al. Impact of TP53 genomic alterations in large B-Cell lymphoma treated with CD19-Chimeric antigen receptor T-Cell therapy. J Clin Oncol: Off J Am Soc Clin Oncol. 2022;40(4):369\u201381.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"1","key":"7974_CR39","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41392-022-00924-0","volume":"7","author":"J Wei","year":"2022","unstructured":"Wei J, Xiao M, Mao Z, Wang N, Cao Y, Xiao Y, et al. Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT. Signal Transduct Tar. 2022;7(1):101\u201311.","journal-title":"Signal Transduct Tar"},{"issue":"14","key":"7974_CR40","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1182\/blood.2020007311","volume":"137","author":"J Ribera","year":"2021","unstructured":"Ribera J, Morgades M, Ciudad J, Montesinos P, Esteve J, Genesc\u00e0 E, et al. Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia. Blood. 2021;137(14):1879\u201394.","journal-title":"Blood"},{"key":"7974_CR41","doi-asserted-by":"crossref","unstructured":"Pourhassan H, Tinajero J, Ma H, Jackson R, Pillai R, Ngo D, et al. The efficacy of targeted and immune-based therapies in adults with TP53-mutated acute lymphoblastic leukaemia. Brit J Haematol. 2025. https:\/\/doi.org\/LID-10.1111\/bjh.20260.","DOI":"10.1111\/bjh.20260"},{"issue":"15","key":"7974_CR42","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","volume":"133","author":"KA Hay","year":"2019","unstructured":"Hay KA, Gauthier J, Hirayama AV, Voutsinas JM, Wu Q, Li D, et al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood. 2019;133(15):1652\u201363.","journal-title":"Blood"},{"issue":"1","key":"7974_CR43","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13045-019-0813-7","volume":"12","author":"X Han","year":"2019","unstructured":"Han X, Wang Y, Wei J, Han W. Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy. J Hematol Oncol. 2019;12(1):128.","journal-title":"J Hematol Oncol"},{"key":"7974_CR44","doi-asserted-by":"publisher","first-page":"1546172","DOI":"10.3389\/fimmu.2025.1546172","volume":"16","author":"S G\u00f3mez-Melero","year":"2025","unstructured":"G\u00f3mez-Melero S, Hassouneh F, Vallejo-Berm\u00fadez IM, Ag\u00fcera-Morales E, Solana R, Caballero-Villarraso J. Tandem CAR-T cell therapy: recent advances and current challenges. Front. Immunol. 2025;16:1546172.","journal-title":"Front. Immunol"},{"issue":"1","key":"7974_CR45","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24(1):20\u201328.","journal-title":"Nat Med"},{"key":"7974_CR46","doi-asserted-by":"publisher","first-page":"217614","DOI":"10.1016\/j.canlet.2025.217614","volume":"617","author":"HH Wu","year":"2025","unstructured":"Wu HH, Leng S, Eisenstat DD, Sergi C, Leng R. Targeting p53 for immune modulation: exploring its functions in tumor immunity and inflammation. Cancer Lett. 2025;617:217614.","journal-title":"Cancer Lett"},{"issue":"13","key":"7974_CR47","doi-asserted-by":"publisher","first-page":"3899","DOI":"10.7150\/jca.113576","volume":"16","author":"J Wen","year":"2025","unstructured":"Wen J, Fu L, Zhong H, Chen H. The role of P53 in immune evasion and therapeutic strategies in hematologic malignancies. J Cancer. 2025;16(13):3899\u2013906.","journal-title":"J Cancer"},{"key":"7974_CR48","doi-asserted-by":"crossref","unstructured":"Davenport AJ, Cross RS, Watson KA, Liao Y, Shi W, Prince HM, et al. Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity. P Natl Acad Sci Usa. 2018;115(9):E2068\u201376.","DOI":"10.1073\/pnas.1716266115"},{"issue":"5","key":"7974_CR49","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1084\/jem.20182375","volume":"216","author":"M Cazaux","year":"2019","unstructured":"Cazaux M, Grandjean CL, Lema\u00eetre F, Garcia Z, Beck RJ, Milo I, et al. Single-cell imaging of CAR T cell activity in vivo reveals extensive functional and anatomical heterogeneity. J Exp Med. 2019;216(5):1038\u201349.","journal-title":"J Exp Med"},{"issue":"22","key":"7974_CR50","doi-asserted-by":"publisher","first-page":"5592","DOI":"10.3390\/cancers13225592","volume":"13","author":"E Porpaczy","year":"2021","unstructured":"Porpaczy E, Wohlfarth P, K\u00f6nigsbr\u00fcgge O, Rabitsch W, Skrabs C, Staber P, et al. Influence of TP53 mutation on survival of diffuse large B-Cell lymphoma in the CAR T-Cell era. Cancers. 2021;13(22):5592.","journal-title":"Cancers"},{"issue":"8","key":"7974_CR51","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/s43018-021-00230-8","volume":"2","author":"F Yang","year":"2021","unstructured":"Yang F, Brady SW, Tang C, Sun H, Du L, Barz MJ, et al. Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse. Nat Cancer. 2021;2(8):819\u201334.","journal-title":"Nat Cancer"},{"issue":"1","key":"7974_CR52","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1182\/blood.2019002220","volume":"135","author":"B Li","year":"2020","unstructured":"Li B, Brady SW, Ma X, Shen S, Zhang Y, Li Y, et al. Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia. Blood. 2020;135(1):41\u201355.","journal-title":"Blood"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-07974-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07974-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07974-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T05:02:41Z","timestamp":1778475761000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-07974-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7974"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-07974-w","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"assertion":[{"value":"7 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. This study was approved by the Ethics Committee of The First Affiliated Hospital of Soochow University. All patients included in this study provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"656"}}